Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P21554 (
cannabinoid receptor
)
3,582
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Under reducing conditions of
SDS
-polyacrylamide gel electrophoresis, the CB(1) receptor exists in its monomeric form as well as in an
SDS
-resistant high molecular weight form that appears to be devoid of G proteins. The CB(1)
cannabinoid receptor
was immunoprecipitated from 3-[(3-cholamidopropyl)dimethylammonio]propanesulfonate-solubilized rat brain membranes using an antibody against the CB(1) receptor N terminus. The CB(1) receptor was coimmunoprecipitated with its associated G proteins, specifically those of the Galpha(i/o) family, but not Galpha(s), Galpha(q), or Galpha(z). The CB(1) receptor-Galpha(i/o) complex existed in the absence of exogenous agonists, and the
cannabinoid receptor
agonist desacetyllevonantradol failed to alter the stoichiometry of the receptor-Galpha(i/o) interaction. Guanosine-5'-O-(3-thio)triphosphate could disrupt the interaction. A peptide derived from the CB(1) receptor juxtamembrane C-terminal domain, peptide CB(1)401-417, autonomously activates G(i/o) proteins. Peptide CB(1)401-417 competitively disrupted the CB(1) receptor association with Galpha(o) and Galpha(i3) but not Galpha(i1) or Galpha(i2). This G protein specificity was also observed in detergent extracts from membranes of the frontal cortex, striatum, and cerebellum. Alternative peptides, including peptides from the CB(1) receptor third intracellular loop and the G protein activating peptide mastoparan-7, failed to promote uncoupling from Galpha(o). A CB(2) receptor juxtamembrane C-terminal peptide failed to disrupt the CB(1) receptor-Galpha(o) complex. These studies illustrate that the CB(1) receptor can exist as an
SDS
-resistant multimer. In 3-[(3-cholamidopropyl)dimethylammonio]propanesulfonate detergent, the CB(1) receptor exists in a complex with G proteins of the G(i/o) family in the absence of exogenous agonists. Furthermore, this study provides the first description of domain specificity for interaction with a selective set of G proteins.
...
PMID:The CB(1) cannabinoid receptor juxtamembrane C-terminal peptide confers activation to specific G proteins in brain. 1061 91
The cytoplasmic helix domain (fourth cytoplasmic loop, helix 8) of numerous GPCRs such as rhodopsin and the beta-adrenergic receptor exhibits unique structural and functional characteristics. Computational models also predict the existence of such a structural motif within the
CB1 cannabinoid receptor
, another member of the G-protein coupled receptor superfamily. To gain insights into the conformational properties of this GPCR component, a peptide corresponding to helix 8 of the CB1 receptor with a small contiguous segment from transmembrane helix 7 (TM7) was chemically synthesized and its secondary structure determined by circular dichroism (CD) and solution NMR spectroscopy. Our studies in DPC and
SDS
micelles revealed significant alpha-helical structure while in an aqueous medium, the peptide exhibited a random coil configuration. The relative orientation of helix 8 within the CB1 receptor was obtained from intermolecular 31P-1H and 1H-1H NOE measurements. Our results suggest that in the presence of an amphipathic membrane environment, helix 8 assumes an alpha helical structure with an orientation parallel to the phospholipid membrane surface and perpendicular to TM7. In this model, positively charged side chains interact with the lipid headgroups while the other polar side chains face the aqueous region. The above observations may be relevant to the activation/deactivation of the CB1 receptor.
...
PMID:The conformation of the cytoplasmic helix 8 of the CB1 cannabinoid receptor using NMR and circular dichroism. 1567 Jul 25